146 related articles for article (PubMed ID: 8463174)
1. Comparative chemotherapeutic activity of temafloxacin, cefoxitin, clindamycin, imipenem and ampicillin/sulbactam against Bacteroides fragilis in a mouse subcutaneous abscess model.
Alder J; Clement JJ
J Antimicrob Chemother; 1993 Feb; 31(2):303-11. PubMed ID: 8463174
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
Brook I
Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of temafloxacin in a rat model of intra-abdominal abscess.
Thadepalli H; Hajji M; Perumal VK; Chuah SK; Gollapudi S
J Antimicrob Chemother; 1992 Jun; 29(6):687-92. PubMed ID: 1324241
[TBL] [Abstract][Full Text] [Related]
5. In-vitro susceptibility and in-vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in mice.
Brook I; Gillmore JD
J Antimicrob Chemother; 1993 Mar; 31(3):393-401. PubMed ID: 8486573
[TBL] [Abstract][Full Text] [Related]
6. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
8. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
Brook I
Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
[TBL] [Abstract][Full Text] [Related]
9. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
Brook I; Ledney GD
J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
[TBL] [Abstract][Full Text] [Related]
11. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
Girard AE; Girard D; Gootz TD; Faiella JA; Cimochowski CR
Antimicrob Agents Chemother; 1995 Oct; 39(10):2210-6. PubMed ID: 8619569
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.
Thadepalli H; Gollapudi SV; Chuah SK
Antimicrob Agents Chemother; 1986 Oct; 30(4):574-6. PubMed ID: 3539011
[TBL] [Abstract][Full Text] [Related]
13. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
[TBL] [Abstract][Full Text] [Related]
14. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
Brook I
J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cefoxitin, cefotetan, and ampicillin/sulbactam as prophylaxis for polymicrobial infection in mice.
Brook I
Clin Infect Dis; 1995 Jun; 20 Suppl 2():S376-7. PubMed ID: 7548603
[No Abstract] [Full Text] [Related]
16. Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.
Zabinski RA; Vance-Bryan K; Krinke AJ; Walker KJ; Moody JA; Rotschafer JC
Antimicrob Agents Chemother; 1993 Nov; 37(11):2454-8. PubMed ID: 8285633
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic sensitivity of the Bacteroides fragilis group in Denmark. Danish Study Group.
Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
APMIS; 1993 Sep; 101(9):727-31. PubMed ID: 8240792
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.
Gisby J; Beale AS
Antimicrob Agents Chemother; 1988 Dec; 32(12):1830-3. PubMed ID: 3072924
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility vs. in vivo efficacy of various antimicrobial agents against the Bacteroides fragilis group.
Brook I
Rev Infect Dis; 1991; 13(6):1170-80. PubMed ID: 1775850
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic penetration of experimental intra-abdominal abscesses.
Galandiuk S; Lamos J; Montgomery W; Young S; Polk HC
Am Surg; 1995 Jun; 61(6):521-5. PubMed ID: 7762902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]